
HTGF et al. back GeneQuine Biotherapeutics
High-Tech Gründerfonds (HTGF) and Innovationsstarter Fonds Hamburg have made a seven-figure seed investment in Hamburg-based biotech company GeneQuine Biotherapeutics.
The capital will be used to fund proof-of-concept studies for the company's lead product, GQ-201, a gene therapy drug for the treatment of osteoarthritis in horses. The business is also working on a similar drug for dogs and plans to target human medicine in the long-term.
The GPs said in a statement they saw potential in the product as it met a medical need of a large veterinary market.
Company
GeneQuine started operating in Hamburg in October 2012. The biotech start-up focuses on the development of gene therapy drugs for the treatment of osteoarthritis in horses, dogs and humans.
People
Investment manager Martin Pfister represented HTGF on the deal. Doreen Huhle is investment manager at Innovationsstarter Hamburg.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater